Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.
Misset JL, Vennin P, Chollet PH, Pouillart P, Laplaige PH, Frobert JL, Castera D, Fabro M, Langlois D, Cortesi E, Lucas V, Gamelin E, Laadem A, Otero J. Misset JL, et al. Among authors: chollet ph. Ann Oncol. 2001 Oct;12(10):1411-5. doi: 10.1023/a:1012556627852. Ann Oncol. 2001. PMID: 11762813 Free article. Clinical Trial.
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Passildas-Jahanmohan J, Eymard JC, Pouget M, Kwiatkowski F, Van Praagh I, Savareux L, Atger M, Durando X, Abrial C, Richard D, Ginzac Couvé A, Thivat E, Monange B, Chollet P, Mahammedi H. Passildas-Jahanmohan J, et al. Among authors: chollet p. Cancer Med. 2021 Apr;10(7):2332-2340. doi: 10.1002/cam4.3806. Epub 2021 Mar 5. Cancer Med. 2021. PMID: 33666378 Free PMC article. Clinical Trial.
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C. Innominato PF, et al. Among authors: chollet p. Int J Cancer. 2021 May 15;148(10):2512-2521. doi: 10.1002/ijc.33422. Epub 2020 Dec 10. Int J Cancer. 2021. PMID: 33270911 Free PMC article.
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karaboué A, Giacchetti S, Bouchahda M, Adam R, Garufi C, Lévi FA. Innominato PF, et al. Among authors: chollet p. Cancer Med. 2020 Jun;9(12):4148-4159. doi: 10.1002/cam4.3056. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319740 Free PMC article. Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
238 results